The body, which is where every claim on this shelf is finally tested, daily and by the handful: the body lotion ranking's own hero, standing at the head of a Take argued from that Card. The frame shows a torso, not a bottle: the photo bank holds no body lotion product photography, no pump-bottle, tub or bathroom-shelf frames, a gap the ranking names on its own page and the honesty section below admits in full.

Checked and updated October 2026

The thesis: the number is in another country

This column keeps finding the same shape of gap on the bathroom shelf, in different units: a claim whose substance is printed incompletely or not at all. The body shelf is the ninth case, and it is the first in which the documents on the page agree with each other. On the shelves before it, something on the buyer's own record always failed: a dose, a duration, an itemised scent, a claimed ingredient standing in no list. Here the buyer's record is, by the standards of this run, exemplary. Every maker publishes his full list. Six makers claim fragrance-free and every one of the six lists cashes the claim. The one bottle sent home was sent home for the run's oldest offence, a retail copy selling a hyaluronic acid neither of its lists carries, which on this shelf reads as an exception precisely because the other seven copies can stand on their lists. And yet the count this column always runs last comes back at its usual figure. Dosed actives: one of eight, and the one is a drug.

Start with what the product is, because the Card is exact about it and the exactness sets the stakes. A body lotion is a coverage instrument: it is bought by the ounce and used by the handful, spread over the largest surface any product in the bathroom touches, and the Card grades it on a body basis built for that use, value priced per ounce at body acreage, format graded as a hygiene record, fit read across the body rather than the face. On a shelf like that, the active is not a garnish. It is the working part of the purchase, the thing the per-ounce price is paying for, and the comparison a buyer is actually making when he holds a $0.42 ounce against a $1.40 ounce is a dose comparison: what does the dearer ounce carry more of? The shelf answers that question with positions. Ceramides at ninth, tenth and eleventh of 24. Shea butter second of 28. Urea seventh of 19. Positions are real evidence, and this column has always read them as evidence; but a position is a rank inside one list, and a rank cannot be spent across two lists, and the buyer on this shelf is choosing across eight. The one figure that travels from bottle to bottle is the percentage, and the shelf prints it once, under compulsion, on the bottle whose active crossed a legal line into drug territory.

The bottle is the Aveeno Daily Moisturizing Lotion, ranked fourth at 79, and its panel deserves reading the way the Card prints it, because it is the shelf's control case. Its active is dimethicone at 1.2 percent, printed on the federal Drug Facts panel, in the panel's own format, because dimethicone sold as a skin protectant is an over-the-counter drug and the law requires the dose on the label. Behind it stand nine inactives, glycerin among them, oat kernel flour seventh of nine, the honest furniture of a drugstore lotion. Nothing about the Aveeno's maker is more transparent than the shelf's other houses; its formula's neighbours on the ranking include houses with longer lists, better paperwork and higher scores. What the Aveeno has that no other bottle on the shelf has is a regulator standing over one of its ingredients. The number is on the bottle because a number was demanded. Where no number is demanded, the identical class of information, the strength of the named active, is printed in documents addressed to other readers, and the sections below count them.

Exhibit one is the Eucerin, ranked fifth at 79, its tie with the Aveeno ruled on the honesty row and printed on both cards. The American record is a 19-item list, identical on the packaging record at two sources: mineral oil second, sodium lactate sixth, urea seventh, glycerin eighth, lactic acid fifteenth. Urea is the formula's named worker, the ingredient the Intensive Repair line is sold on, and it stands in the list's upper half with no figure beside it. The same house, across the Atlantic, sells a UreaRepair line whose products are named by the number this bottle withholds: urea dosed at 5 percent and at 10 percent, printed as the line's identity, the figure a European buyer chooses between before he chooses a bottle. The desk did not have to estimate the American bottle's strength from a rival's paperwork or a supplier's panel. The maker's own European catalogue is the estimate's source, and it is a catalogue the maker publishes proudly, in the open, to buyers. The number exists in the maker's files, in the maker's marketing and on the maker's European shelf. On the American bottle it is a position, seventh of nineteen, and the distance between those two documents is the whole of this issue.

Exhibit two is the Lipikar, ranked third at 81, the balm the shelf's sensitive cases are built around, and its record has the same shape in a different channel. The consumer record is a coded list of 28 items: shea butter second, glycerin third, niacinamide fifth, Ceramide NP thirteenth, Vitreoscilla Ferment twenty-third. The maker prints, in its pharmacy-channel materials, the figures the consumer record omits: shea butter at 20 percent, glycerin at 8 percent. Those are the two numbers a buyer comparing balms would spend first, the strength of the formula's foundation, and they are published, by the maker, in a document written for pharmacists. A reader who wants them can find them, if he knows they exist, knows which channel holds them and reads professional materials for pleasure. The buyer standing in the aisle with the bottle in his hand is handed positions instead: second and third, which tell him the balm is built on shea and glycerin and cannot tell him whether the $1.40 ounce, the dearest ranked ounce on the shelf, carries twice the shea of a cheaper balm or a tenth more. The desk grades the record the buyer is handed. On that record the Lipikar's dose is a rank, and its percentage is in another document.

Set the two exhibits against the shelf and the pattern completes itself. The CeraVe, the winner at 84, prints its three named ceramides at ninth, tenth and eleventh of 24, no figure beside any of them. The Vanicream, the field's honesty winner at 82, publishes the shelf's shortest list, eleven items, and an absence list that is a model of the genre, and doses nothing. The Gold Bond prints its three vitamins at nineteenth, twentieth and twenty-first of 27, undosed, above a Fragrance entry standing last under a hypoallergenic claim no federal standard defines. The Lubriderm's American panel runs 18 items, panthenol seventh, and doses nothing either; its failures are of the older species and the record section counts them. Four of the eight bottles circulate more than one list, and the desk reads that divergence as the shelf's paperwork moving in the open. Through all of it, the percentage column stands where it stood: one entry, a drug panel, zero volunteers. The one other percentage anywhere in the Card's orbit belongs to a rested product, the CeraVe Intensive Moisturizing Cream, whose Target record prints a 5 percent Hydro-Urea figure, a number standing on a retail record for a bottle the Card did not grade. Even the shelf's spare dose is in a document one step removed from a label.

Nothing on this page is scored. Every score quoted here, every row, every price and every count is the body lotion ranking's, Verdict Card No. 92, reproduced exactly as that Card published it: CeraVe Moisturizing Cream at 84, Vanicream Moisturizing Cream at 82, La Roche-Posay Lipikar Balm AP+, now Lipikar AP+M Triple Repair, at 81, Aveeno Daily Moisturizing Lotion at 79, Eucerin Intensive Repair Lotion at 79, Lubriderm Daily Moisture Lotion at 75, Gold Bond Ultimate Healing Lotion at 70, and NIVEA Essentially Enriched Body Lotion sent home at 53. The only arithmetic of this page's own is counting what the Card's record prints: how many lists are published whole, how many claims are cashed, how many actives are dosed and where the percentages that exist are addressed. Two precisions in this issue's own brief, the geography of its title and the sharpening of its central count from one of eight to zero of seven volunteering, are confessed in the honesty section, in words, because a column about grading documents should print its own corrections where its readers can find them.

The record, counted

Start with the list column, because its completeness is what makes this census different from every census before it, and because the completeness is the argument's foundation rather than its decoration. Full ingredient lists published: eight of eight. Provenance varies and the Card prints the variation: the winner's list read on its retailer's panel and identical to the two-retailer record Card No. 66 graded; the Vanicream's read on the maker's own record through its allergy channel; the Lipikar's the maker's coded list; the Aveeno's a federal drug panel; the Eucerin's the packaging record at two panels in agreement; the Lubriderm's the current American panel at two retailers; the Gold Bond's the current 27-item grocery panel; the skip's the packaging record, with a 14-item retail rendering of the same bottle counted beside it. Against that base the shelf's four columns can be counted separately: the claim, the scent, the dose and the divergence.

The claim column first, since it is the census's surprise. Fragrance-free claims made: six of eight. Fragrance-free claims cashed by the maker's own published list: six of six. This column has counted claim failures on every shelf it has visited, claims of actives absent from lists, claims of absence contradicted by lists, claims dressed in borrowed percentages. On the body shelf the ordinary traffic between copy and list is, for once, honest, and the failures concentrate in the two records the Card charges for them. The Lubriderm's retail copy leads with a Pro-Ceramide that stands on no published list, its 18-item American panel carrying no ceramide entry of any kind, and paraben-free copy floats above a panel that closes on three parabens: two sentences of the older species, charged on its card and priced in its 75. The skip's copy sells a hyaluronic acid that neither circulating list contains, beside a 72-hour claim where 48 stood before, and it is sent home at 53. And the Gold Bond prints hypoallergenic, a word no federal standard defines, on a bottle whose list ends in Fragrance. Three records with copy problems, five without, and the shelf's centre of gravity is paperwork that agrees with itself. That is the base the dose column has to be read against: not a shelf of careless documents, but a shelf whose documents are careful everywhere except the one column that would let a buyer compare strength.

The scent column is the census's control case, and it is short. A Fragrance or Parfum entry: two of eight lists, the Gold Bond's standing twenty-seventh and last of 27 and the skip's twelfth of 15. Six makers keep fragrance out of the category's workhorse product entirely and say so in claims their lists then cash, the discipline this run has watched other shelves fail at every price. The count matters to this issue for the same reason the eye shelf's fragrance count mattered to the last one: it proves the shelf's documentation is a choice exercised well wherever the makers choose to exercise it. A category that can standardise an honest absence claim across six competing houses, and print absence lists like the Vanicream's, a document that enumerates what is not in the bottle across six categories of material, has demonstrated every documentary skill the dose column would require. The skill is present. The number is absent. The difference between the two columns is not ability and it is not custom inside the category, because the category's custom, on the evidence of its own lists, is to print what the buyer asks about. Buyers ask about fragrance. The lists answer. Buyers ask about strength. The lists give them a rank.

The dose column is the census's centre, and its numbers are two: one of eight, and zero of seven. One of eight records prints a percentage for its headline active on the document the buyer reads: the Aveeno's dimethicone at 1.2 percent, on the Drug Facts panel, under federal compulsion. Zero of the seven cosmetic records prints one voluntarily. Everything else on the shelf travels on position: glycerin second of 24 in the winner, petrolatum second of 11 in the Vanicream, shea second and glycerin third of 28 in the Lipikar, urea seventh of 19 in the Eucerin, panthenol seventh of 18 in the Lubriderm, the Gold Bond's vitamin trio at nineteenth, twentieth and twenty-first of 27. Position is ordinal evidence, descending by weight to the one percent line, and this column reads it as evidence on every shelf. But a rank is a fact about one list, and the shelf is eight lists, of eleven items and of twenty-eight, and no arithmetic turns seventh of nineteen into a quantity a buyer can set against thirteenth of twenty-eight. Now the elsewhere column, which is what makes this census new. Percentages in the makers' further documents: the Eucerin's house doses urea at 5 and 10 percent in its European line's own names; the Lipikar's maker prints 20 percent shea butter and 8 percent glycerin in pharmacy-channel materials; and a rested bottle at the Card's edge, the CeraVe Intensive Moisturizing Cream, carries a 5 percent Hydro-Urea figure on its retail record, ungraded and first in line for a follow-up Card. Three percentages in the Card's orbit, addressed to a European catalogue, a professional channel and a retail panel for a bottle not in the field. On the eight labels the buyer can read in the aisle, one, and that one a drug's.

The divergence column closes the count, because it is the shelf's proof that its paperwork is alive, and living paperwork is the counter-argument's favourite fact, counted here first. More than one list in circulation: four of eight. The Lubriderm carries three documents under one name, the current American panel of 18, the legacy list Card No. 66 read, and a European rendering carrying shea butter, oat kernel oil and a Parfum entry last, a scented document travelling under a fragrance-free flagship's name. The Gold Bond's older list runs 29 items with hydrolysed collagen, hydrolysed elastin and a vitamin A ester aboard, where the current list runs 27 and has quietly landed all three. The skip's list runs fifteen items on the packaging record and fourteen on one retail panel, the dropped item tocopherol. A retail rendering of the Lipikar adds a pea extract and a cyclodextrin to the maker's coded 28. The desk grades the maker's or the label's current document in every case and prints the divergence on every card, and the desk's conclusion is the run's standing one: a document in this year's bottle may not be the document a reader checked last year. But note what the divergence proves for this issue. These houses maintain their lists, revise them, render them for channels and markets, land ingredients and embark them, at the cost of real editorial labour. The documents are worked on. The one figure that never appears in any revision is the dose of the active the bottle is sold on, and a figure that survives every revision by its absence is not an oversight. It is a policy with a geography.

What the elsewhere dose costs

The first cost is comparison, and on this shelf it falls exactly where the money is. The ranked ounces run from the Lubriderm's $0.42 through the winner's $1.25 to the Lipikar's $1.40, a spread of more than three to one, and the natural reading of that spread is that the dearer ounce carries more of something. On this record the buyer cannot test the reading. He can compare positions, which rank inside lists and stop at their borders; he can compare list lengths, which measure paperwork, not strength; he can compare claims, which on this shelf are honest and therefore mostly about absence. What he cannot do is the one sum the shelf exists to help him do, which is to divide a price by a dose. The European buyer of the same house's urea line does that sum before he opens his wallet, because the line is sold as a choice between 5 and 10. The American buyer of the same house's lotion is offered a rank, seventh of nineteen, and a price, and the two numbers cannot be brought into relation. A shelf where price can be divided by everything except the active is a shelf where the active's strength has been priced as a matter of faith, and the makers who print positions honestly, seven of eight here, are the ones whose faith is being spent.

The second cost is the screening reader's, and the body shelf is where he works hardest. A reader who screens for an ingredient, the sensitive case this category serves, is well served here: the Vanicream publishes an absence list that is the genre's model, the fragrance-free claims cash six for six, the lists are complete. A reader who screens for strength, who has been told by a clinician to use a urea preparation, or who is choosing a balm for a barrier case and needs to know whether the shea is a foundation or a flavouring, is served a rank and sent elsewhere. The elsewhere exists, and the Card found it, in a European catalogue and an Irish pharmacy's materials, which is to say the screening reader's diligence is taxed in proportion to the seriousness of his question. The casual question, is it fragranced, is answered on the bottle. The clinical question, how much urea, is answered on another continent. The shelf has arranged its documents so that the questions get harder to answer as they get more medical, and it has done so while selling to exactly the readership, the eczema and barrier cases the NEA seals on these cards attest, whose questions are the medical ones.

The third cost is paid by the makers themselves, and the ranking prints it in the order. The shelf's first and second bottles are its two most documented: a winner whose list is complete, whose claim is cashed and whose format failure, the open tub, is charged in the open on its own card; and a runner-up whose eleven items and published absences are the fullest disclosure relative to formula size in the field. The two exhibits of this issue, the Eucerin and the Lipikar, stand third and fifth, and nothing in their ranks says their formulas are weak; their active records are graded 18 and 16 of 20, the field's two best, on positions that suggest built formulas. What their ranks cannot express, because the Card grades documents, is whether their strength would carry them higher if it were printed where the buyer stands. A maker who has paid to formulate at 20 percent shea and then declines to print the figure on the bottle has bought an asset and declined the receipt. The desk cannot grade the asset; it can only note that the one maker forced to print a dose by law stands fourth with the shelf's plainest formula, and that the two makers holding the shelf's most printable numbers have left them in other countries' documents, where they earn nothing.

The fourth cost is escalation, and this shelf prints the staircase in its mildest form yet, which is what makes it worth printing. The first step is position: an active present, high, undosed, sold on its rank, which is the whole shelf's step and is charged nowhere, because the ingredient is at least employed and placed. The second step is the elsewhere figure: a percentage that is real, published and addressed to somebody else, a professional channel, a foreign line, riding near the bottle in the maker's wider paperwork and lending the bottle an air of measured strength it never quite claims. The third step, the assertion, an ingredient claimed where no list carries it, stands on this shelf only in the Lubriderm's retail copy and the skip's, and both are charged. The staircase is climbed in the direction the money points, and the second step is the comfortable one, because it is defensible in every particular: the number is true, the number is published, the number is the maker's own. Its only defect is its address. A column that lets the second step pass as transparency will find the third step easier to defend next season, since both borrow a document's authority for a sentence the buyer's document does not contain. The shelf also prints its antidote, and it is a legal one: the drug panel, where a regulator has simply required the number and the number has simply appeared, at no visible cost to the Aveeno's sales, its formula's secrecy or its maker's dignity. Compulsion is not this column's programme. But the panel stands on the shelf as proof of what the number costs to print, which is nothing, and that proof is the answer to every defence of the elsewhere dose that has ever been offered.

The other side, stated fairly

The case against this Take is a serious one, and it runs in three parts. First: a percentage misleads as readily as it informs. Twenty percent shea butter in a balm and twenty percent in a lotion are different instruments; a figure says nothing about the vehicle that carries the active, the emulsifier system that delivers it, the skin it lands on or the quantity a user actually applies, and a body lotion is applied by the handful over acreage, so the delivered dose varies more by the handful than by the formula. Position, by contrast, is the honest consumer signal the law designed: lists run in descending order of weight to the one percent line, so second of 28 and seventh of 19 are dose facts in ordinal form, printed on every bottle, and a column demanding percentages is demanding a false precision the chemistry cannot cash. Second: no regime compels the number, and the absence is a policy, not a dodge. Cosmetic formulas are trade secrets in the United States and in Europe alike; the European Union does not require percentages on cosmetic labels either, and the figures this Take exhibits are a maker's voluntary marketing in a pharmacy-led market culture, while the dosed documents that circulate from the United Kingdom belong to a drug-licensed cream, a different legal creature. The one American dose on the shelf exists because dimethicone crossed into drug law. To grade cosmetic labels against a drug panel's standard is to grade one legal category by another's rules. Third: the elsewhere documents are not hidden. Pharmacy materials are professional documents because professionals ask formulation questions; the consumer record is a consumer document, and it is complete in everything a consumer record is for: the full list, the honest claims, the format, the price. A buyer who wants the pharmacy file can read it; nothing is withheld from him that is his, and a channel difference has been dressed up in this Take as a withholding, with a map attached for colour.

Each part is true about something, and the record answers each on its own ground. To the false precision: conceded that a percentage is not a formula, and refused as a defence of printing none. This desk has never asked for a formula; it asks for the headline active's dose, one number, and the makers themselves rule on whether the number is meaningful every time they print it. The UreaRepair line is not merely compatible with percentages; it is organised by them, sold as a choice between 5 and 10, which is the maker's own verdict that a buyer can spend the figure wisely. The same house cannot hold the number definitional in one market and meaningless in another. As for position being the designed signal: it is, and this column reads it on every shelf, and it has two limits the counter does not mention. Below the one percent line, order is free, so the tail of every list is dose-silent by design; and across lists, ranks do not convert, so the signal works only inside a bottle the buyer has already chosen. A ranking is a cross-bottle instrument. The signal the counter praises cannot be spent on the decision the shelf exists for, and the percentage, with all its imprecision confessed, is the only figure that can. Imprecise and comparable beats exact and incomparable, for a buyer, every time.

To the regimes: the explanation is conceded entire, and it explains the wrong thing. That no law compels the number is the desk's own finding; the Aveeno's panel is this issue's exhibit of what compulsion produces. But the grade is not of the regime. It is of the document the buyer is handed, and the desk's standing question is what that document lets him decide. The trade-secret limb, meanwhile, meets the shelf's own record: a percentage for one named active discloses no formula, as the drug panel itself proves, standing as it does over nine undisclosed inactives; and the houses on this shelf already publish their complete lists, in order, which is a far larger disclosure than one figure beside one name. A maker who prints all twenty-eight ingredients in their order has not protected a secret by withholding the strength of the second one. He has protected a comparison. The European limb proves the same point from the other side: where a market culture asks for the number, the identical houses print it without legal injury. The number's geography follows the asking, which is this Take's thesis restated by its opposition.

To the channel: the desk grades documents at the point of sale, as it did on the eye shelf, because the point of sale is where the reader this site serves is standing. A pharmacy file a buyer does not know exists, in a channel he does not shop, in a market he does not live in, is published in the sense that a lighthouse is a reading lamp: the light is real and it is not in his room. The claim that nothing is withheld that is his assumes the conclusion, since what is his is precisely what the exchange entitles him to, a document from which he can judge what he is buying, and on dose the consumer record lets him judge nothing across the shelf's own prices. The channel defence also meets the shelf's control case. The fragrance question is answered on the bottle, in claims and in absence lists, because the makers judged it a consumer question. The strength question is answered in a professional file, because the makers judged it a professional one. The buyer spreading a balm over a barrier case by the handful is entitled to ask who made that judgment, and on what evidence about his competence, and the record shows the judgment was not made about him at all. It was made about the comparison he would run if he could. The map is not colour. It is where the comparison went.

The picks, as published on the Card

The discipline for using any of them is the Card's, unchanged: a body lotion is applied to damp skin, by the handful, in the minutes after washing, and the pump is bought where the household shares the bottle because hands go back into tubs. The standing offer of this column applies to the shelf in its own terms: the first maker on this shelf to print his headline active's dose on the American consumer record, on the label or the product page a buyer reads, rather than in a European line's name or a pharmacy file, will be named here, at the top of a re-argued column, the same day its record can be read. The documents exist in every maker's files, and two of them are already written. They are simply addressed to somebody else.

What this page does not claim

On the evidence. This page scores nothing and tests nothing. Every score, row, price and position is Verdict Card No. 92's, reproduced exactly as that Card published it, and the Card's own evidence discipline stands behind them: the desk grades published ingredient lists in the maker's order, makers' claims graded as claims, reported wear labelled as reported wherever it appears, and prices per ounce with the arithmetic printed, and asserts nothing about what any lotion does to any skin. The counts this Take adds, full lists on eight of eight, fragrance-free claims cashed on six of six, a dosed active on one of eight and none by choice, a Fragrance entry on two, three percentages circulating in further documents, are counts of the Card's printed record and are printed as counts so they can be recounted.

On the brief's premises, and the two precisions this issue carries. This issue was briefed on four counts, and all four survived the record: full lists standing on eight of eight records; fragrance-free claims cashed six for six; an active carrying a printed percentage on one of eight American consumer records, that one an over-the-counter drug panel; and the same houses printing their percentages elsewhere, the Eucerin's urea dosed in Europe and undosed seventh on the American list, the Lipikar's shea and glycerin percentages standing in pharmacy materials and nowhere on the consumer record. Two precisions are printed rather than absorbed. First, the geography in this issue's title is literal for the two named cases and is not the load-bearing fact: the UreaRepair figures are a European line's, the pharmacy materials were captured from an Irish pharmacy channel, and the dosed-urea documents at 10 percent that circulate in search results are a United Kingdom drug-licensed cream, a different product from the American lotion graded here, a conflation the Card itself flags and this Take does not repeat. The argument survives the map's removal, because a trade channel in the buyer's own country would keep the number from the label in his hand just as completely; what is withheld is withheld from an audience, and the country is where the audience happens to be. Second, the central count is sharper than the brief's one of eight: the one dosed bottle is dosed to the buyer, on its bottle, because federal law compels it, so the voluntary count is zero of seven cosmetic records, and the Take prints the sharper count as its finding, that on a shelf of complete lists and cashed claims, no maker doses his active by choice.

On what body lotions do. Nothing on this page says any lotion heals, repairs or moisturises any body, and nothing says any dose of urea or shea butter is the right dose for any reader. Efficacy is graded nowhere here: where a figure like the UreaRepair line's 5 and 10 percent is discussed, it is discussed as a published number and a purchasing instrument, not as a recommendation of either strength. What is graded is the document the buyer is handed: where the actives stand, what is dosed and where the dose is addressed. The desk opened no tub and spread no lotion. The argument is about what is printed for a reader to read before the handful, and on eight labels what is printed is everything except the strength of the thing being bought.

On the photographs, and on the record moving. There are no photographs of ranked products on this page because there are none to print: the photo bank holds no body lotion product photography, no pump-bottle, tub or bathroom-shelf frames, a gap the Card names on its own page, and the hero and figure here are frames of the subject itself, the ranking's own hero and a studio frame of the back, the surface this shelf is spread over, captioned for what they show, which is a wearer, not a product. The record itself moves underneath this argument: prices drift by door (the Eucerin standing at $15.49 at its graded door and $12.79 at Target, both printed on its card); documents diverge (the Lubriderm's three lists under one name, the Gold Bond's landed ingredients, the Lipikar's retail rendering with two extra items, each owed to the November pass); one name has already moved (the Lipikar's American shelf name is now AP+M Triple Repair, printed on its card); and one rested bottle waits with a percentage already standing on its retail record, the CeraVe Intensive Moisturizing Cream and its 5 percent Hydro-Urea, first in line for a follow-up Card, whose pass will be the next reading of this shelf's dose count. The scores and the rule stand as published until a cited record changes; when one does, the Card moves first and this Take is re-argued from it, in the open.

Questions, answered from the record

Next

The record this issue argues from stands in full at the body lotion ranking, Verdict Card No. 92, where every list quoted here is printed in its maker's order and every bottle carries its own card. The shelf above the sink continues at the moisturizer Card, No. 66, where this shelf's winner, runner-up and sixth bottle were first graded on the face basis, the serum Card, No. 91, the body wash Card, No. 69, and the eye cream Card, No. 90, and the routine that orders them stands at the skincare Decoder. The kinship runs three ways: Take No. 2 is the parent argument, of which this shelf is the second case, since there the number nobody prints stood printed nowhere the column could find, and here the number exists, is published, and is addressed to somebody else, so the blank has moved from the maker's files to the buyer's label; Take No. 7 governs the existence half, the number is not the dose, since a percentage that stands in another market's document doses no bottle on this shelf, exactly as a rating printed without its dose beside it dosed nothing there; and Take No. 13 is the nearest sibling, the copy is not the list, since there the documents on one page disagreed because the copy claimed more than the list carries, and here they disagree in the other direction, the maker's further documents knowing more than the label says, and both are graded where the buyer stands; and No. 15, the rinse is not the dose, where the acid shelf prints its strengths on four of eight records and its pH on three and still means something different by each number, the dosed records standing on the leave-ons and the timed peel, the rinse-off acids carrying the name without the number, and the shelf's strongest bottle rationed by its own maker to ten minutes twice a week. The franchise so far: No. 1, grooming is sold by the step and works by the habit; No. 2, the number nobody prints; No. 3, one tube, two honesties; No. 4, the pair graded as one record; No. 5, the name is not the number; No. 6, the name is not in the list; No. 7, the number is not the dose; No. 8, the minute is the dose; No. 9, the ritual is not an ingredient; No. 10, the hold is an adjective; No. 11, the name is not an ingredient; No. 12, the burn is not the proof; No. 13, the copy is not the list. How every score on this site is built is set out in the methodology. The Takes continue by number; the next one starts, as this one did, from a record that already exists or a blank that is printed as one.